Month: May 2022

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results expected in June 2022 Epilepsy Day showcases largest targeted epilepsy portfolio in industry Cash and investments of $222.5 million as of March 31, 2022 supports runway into 3Q23 BOSTON, May 09, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update, including a video highlighting recent business and pipeline progress, and reported financial results for the first quarter 2022. “This...

CarGurus Announces First Quarter 2022 Results

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

First Quarter Highlights:Total revenue of $430.6 million, an increase of 151% year-over-year GAAP operating income of $26.7 million; non-GAAP operating income of $62.2 million GAAP consolidated net income of $18.8 million; non-GAAP consolidated net income of $48.9 million GAAP net loss attributable to common stockholders of ($62.1) million; non-GAAP net income attributable to common stockholders of $42.9 million Cash, cash equivalents and short-term investments of $375.0 million and no debt Consolidated Adjusted EBITDA of $65.7 million; Adjusted EBITDA of $58.0 millionCAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) — CarGurus, Inc. (Nasdaq: CARG), a multinational, online automotive platform for buying and selling vehicles, today announced financial results for the first quarter ended March 31, 2022. “2022 is off to a...

Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitisIndependent Data Monitoring Committee (DMC) recommends advancing to Phase 3Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. “We were pleased to recently announce positive top-line data from our FILLMORE trial in chronic pouchitis patients, the first of four important AMT-101 Phase 2 readouts,” said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT....

PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results and Declares a Quarterly Dividend of $0.30 Per Share

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

DELRAY BEACH, Fla., May 09, 2022 (GLOBE NEWSWIRE) — PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter and fiscal year ended March 31, 2022. Net sales for the quarter ended March 31, 2022, were $66.0 million, compared to $71.7 million for the comparable quarter in the prior year, representing a decrease of 7.9%. Net income of $6.1 million, or $0.30 diluted earnings per share, for the quarter ended March 31, 2022, declined 11% from net income of $6.8 million, or $0.34 diluted earnings per share, for the prior year quarter ended March 31, 2021. Adjusted EBITDA (1) was $9.5 million, or $0.47 diluted per share, for the current year quarter, compared to adjusted EBITDA of $10.4 million, or $0.52 diluted per share, for the quarter ended March 31, 2021. Net sales for the fiscal year ended March 31,...

Atrion Reports First Quarter 2022 Results

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

ALLEN, Texas, May 09, 2022 (GLOBE NEWSWIRE) — Atrion Corporation (NASDAQ: ATRI) today announced its results for the first quarter ended March 31, 2022. Revenues for the first quarter of 2022 totaled $47.1 million compared to $39.2 million for the same period in 2021. For the quarter ended March 31, 2022, operating income was $10.3 million, up $1.3 million over the comparable 2021 period, and net income was $8.5 million, up $800 thousand over the same period in 2021. First quarter 2022 diluted earnings per share were $4.71 compared to $4.22 for the first quarter of 2021. Commenting on the results for the first quarter of 2022 compared to the prior year period, David Battat, President and CEO, stated, “Revenues were up 20% and operating income was up 15%, despite the impact of the pandemic and higher costs due to supply and labor...

aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update

Written by Customer Service on May 9, 2022. Posted in Earnings Releases And Operating Results.

Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022. FDA granted orphan drug designation for efzofitimod for the treatment of systemic sclerosis; company to explore potential expansion of clinical program in other ILD. Ended the first quarter 2022 with $98.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, May 9th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology...

RGC Resources, Inc. Reschedules Second Quarter 2022 Earnings Call

Written by Customer Service on May 9, 2022. Posted in Public Companies.

ROANOKE, Va., May 09, 2022 (GLOBE NEWSWIRE) — RGC Resources, Inc. (NASDAQ: RGCO) will host its rescheduled quarterly conference call and webcast to review the results of its fiscal second quarter on Wednesday, May 11, 2022 at 9:00 a.m. eastern time. Related presentation materials are available before the call on the Company website on the Investor & Financial Information page at https://www.rgcresources.com/investor-financial-information/. The call has been rescheduled due to technical difficulties encountered in the originally scheduled call. Interested parties may access the conference call by dialing toll-free 1-866-705-2554 and entering conference identification number 917621. An archive of the webcast will be available for one year on the website at https://www.rgcresources.com/investor-financial-information/. RGC Resources,...

Tauriga Sciences Inc. Chief Executive Officer Completes 1,500,000 Share Insider Purchase

Written by Customer Service on May 9, 2022. Posted in Public Companies.

New York, NY, May 09, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences and Pharmaceutical Development Company, today announced that its Chief Executive Officer, Seth M. Shaw, completed an insider purchase for 1,500,000 shares of Tauriga Sciences Inc. common stock (quoted on the OTCQB – symbol: “TAUG”). This Insider Purchase was completed between the dates of May 5-9, 2022 and a corresponding Form 4 will be filed this week. E-Commerce Website: www.taurigum.com ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products...

Fagron shareholders approve all voting items AGM and EGM

Written by Customer Service on May 9, 2022. Posted in Public Companies.

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 May 2022 Fagron shareholders approve all voting items AGM and EGM Today, Fagron held its annual general meeting of shareholders (AGM) and extraordinary general meeting of shareholders (EGM). The AGM and the EGM approved all voting items. The AGM approved, amongst other things, Fagron’s 2021 financial statements and the gross dividend of €0.20 per share over 2021. Also, Vera Bakker, Ann Desender, and Neeraj Sharma were appointed as independent and non-executive directors, and Management Deprez BV, represented by Veerle Deprez, was reappointed as independent and non-executive director, each for a four-year term. Rafael Padilla and Karin de Jong were reappointed as executive directors, also each for a four-year term. Other voting items approved by the AGM include Fagron’s...

Natural Gas Services Group, Inc. Reports First Quarter 2022 Financial and Operating Results

Written by Customer Service on May 9, 2022. Posted in Public Companies.

Midland, TX, May 09, 2022 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (NYSE:NGS), a leading provider of gas compression equipment and services to the natural gas industry, announces the following conference call information for their first quarter 2022 earnings release: Earnings Release: Monday, May 16, 2022 after market closesPublic distribution will be through Intrado Digital Media and the Natural Gas Services Group, Inc. website at www.ngsgi.com. Conference Call: Tuesday, May 17, 2022 at 10:00 a.m. Central, 11:00 a.m. EasternLive via phone by dialing 877-358-7306, pass code “Natural Gas Services”. All attendees and participants to the conference call should arrange to call in at least 5 minutes prior to the start time. Conference Call Replay For those unable to attend the live teleconference, a Webcast replay...

Month: May 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals